Results for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental's Board approved unaudited results for Q3FY26 and 9MFY26 on February 14, 2026, with an unmodified opinion from auditor V Goswami & Co. Standalone revenue from operations rose to ₹1,275.12 lakhs in Q3 (up 11.6% YoY from ₹1,142.82 lakhs), though 9-month standalone revenue fell ~25.5% to ₹3,863.74 lakhs. Standalone profit after tax improved to ₹61.15 lakhs in Q3 (up from ₹54.66 lakhs) but slipped to ₹175.95 lakhs for 9M from ₹203.27 lakhs. On a consolidated basis, Q3 revenue jumped ~52% YoY to ₹1,984.21 lakhs, but 9M consolidated results swung to a loss of ₹64.79 lakhs from a ₹388.35 lakh profit last year, largely dragged by subsidiaries reporting net losses of ₹1,040.74 lakhs for the 9-month period.
Mixed signals for shareholders: improved standalone quarterly performance is offset by weaker 9-month trends and a consolidated loss driven by loss-making subsidiaries. Note that prior period figures have been restated due to a change in joint venture accounting method (from proportionate consolidation to equity method), which affects year-on-year comparability.